A new ADHD medicine arrived this year. Here is the whole picture.

Two decisions, three months apart

The story has two dates. On July 24, 2026, the Food and Drug Administration approved centanafadine, sold as Simtriyo, for attention-deficit/hyperactivity disorder in adults and in patients aged 6 and older weighing at least 20 kg. Then, on October 30, 2026, the Drug Enforcement Administration placed centanafadine in Schedule III of the Controlled Substances Act, in an interim final rule that took effect that day, with public comments open until November 30, 2026. The second step was not a formality added for drama. The FDA approval letter tied marketing to scheduling being completed, because the medicine is a stimulant with abuse potential. Coverage that treats July's approval as the day the medicine became available skips that gate, and coverage that treats October's rule as a warning sign misses its purpose, which was to let a newly approved medicine be marketed under defined controls without undue delay.

A familiar job, done by a wider tool

ADHD medicines mostly work on the brain's signaling for attention and impulse control. The established stimulants raise the availability of dopamine and norepinephrine. Centanafadine's label names three messengers instead of two: it is a norepinephrine-dopamine-serotonin reuptake inhibitor, meaning it slows the reabsorption of all three. Serotonin is better known from antidepressants, which is one reason early stories about this medicine sounded confused, sometimes calling it a non-stimulant and sometimes an antidepressant cousin. The FDA label settles both points. It classifies centanafadine as a central nervous system stimulant, with the stimulant boxed warnings attached, and its approved use is ADHD, rated on ADHD symptom scales. A wider mechanism is interesting science and a real expansion of the prescriber's shelf. It does not tell any individual patient, in advance, that this tool will fit their brain better than the narrower ones.

What six weeks of evidence can hold

The label's clinical studies section describes four randomized, double-blind, placebo-controlled trials, each six weeks long. The younger studies randomized 480 children aged 6 to 12 and 459 adolescents aged 13 to 17, using the ADHD Rating Scale-5. The adult studies randomized 466 and 440 adults aged 18 to 55, using the Adult ADHD Investigator Symptom Rating Scale, and they tested a different formulation of the same medicine, which the label treats as equivalent in effect to the approved capsule. In total, 1,845 people took part. Symptoms fell further on centanafadine than on placebo in every study, by margins that were statistically significant and, in size, modest: the advantage over placebo ran from 2.7 to 5.6 points on the scales used. Placebo groups also improved substantially, a result worth pausing on. Six weeks of scheduled visits, symptom tracking, and structured attention to the problem moved scores on their own. That is not an argument against medicine. It is part of why ADHD care pairs medicine with structure rather than asking a capsule to carry the whole plan.

The comparisons that were never run

Read the approval carefully and two absences stand out. No trial pitted centanafadine against methylphenidate, an amphetamine product, atomoxetine, viloxazine, or any other approved ADHD treatment, so there is no evidence ranking it among them. And no trial ran longer than six weeks, so the label is silent on how benefits and side effects settle over a school year, a job, or a decade, which is the timescale on which ADHD treatment actually happens. Claims now circulating about emotional regulation or executive function go beyond what these approval trials were built to prove, which was change on standard ADHD symptom rating scales. The measured claim is the one to keep: a new class of stimulant outperformed placebo, modestly, over six weeks, in children, adolescents, and adults. Patients doing well on an existing medicine have no evidence-based reason to switch toward an unknown. Patients doing poorly have a new, legitimate option to discuss, with its unknowns named.

Safety, stated the way the label states it

The prescribing information carries a boxed warning with two subjects. In the six-week study of children aged 6 to 12, suicidal thoughts and behaviors occurred at higher rates on the medicine than on placebo, and the label requires close monitoring of pediatric patients for those symptoms, for clinical worsening, and for unusual changes in behavior, above all early in treatment. The second subject is abuse, misuse, and addiction, the standard stimulant warning, sharpened by the observation that misuse can end in overdose and death. Among adults, the adverse reactions seen in at least 5 percent of treated patients and more often than on placebo were headache, decreased appetite, insomnia, nausea, dry mouth, and diarrhea. The label further warns that blood pressure and heart rate may rise, that people with serious heart disease should avoid the medicine, that new psychotic or manic symptoms may emerge, that tics may appear or worsen, and that combining it with other serotonergic medicines may cause serotonin syndrome. That last point deserves emphasis in combined care, because many adults with ADHD also take an antidepressant, and a prescriber needs the whole list before judging fit.

Where therapy and structure fit next to a new medicine

A new approval changes the medication shelf. It does not change what the rest of ADHD care is for. Therapy and coaching work on the systems a medicine cannot install: how a day is planned, how a task is started, how a lapse is recovered from, how shame about missed obligations is handled before it becomes avoidance. Skills work also produces the observations that make medication decisions good ones, because a patient who tracks sleep, appetite, focus windows, and late-day rebound can describe a medicine's real effect instead of a general impression. If this medicine enters your plan at some point, that tracking becomes more valuable, not less: it was studied for six weeks, so the honest way to use it is as a defined trial with agreed measures, reviewed on schedule, and stopped or kept based on what the record shows. And if it never enters your plan, because your current treatment works, that is also the evidence speaking. The goal was never the newest medicine. It is a life that runs better, by whichever combination gets there.

Sources

Everything in this article traces back to the regulator sources below. Figures are taken from the FDA prescribing information and the Federal Register rule.

U.S. Food and Drug Administration prescribing information for Simtriyo (centanafadine), NDA 218145, revised October 2026: the approved indication, the boxed warnings, the warnings and precautions, the most common adverse reactions, and the four clinical studies in section 14. FDA prescribing information.

U.S. Food and Drug Administration approval letter for NDA 218145, July 24, 2026: the application is approved for the treatment of attention-deficit/hyperactivity disorder, and marketing was tied to completion of controlled substance scheduling. FDA approval letter.

Drug Enforcement Administration, Schedules of Controlled Substances: Placement of Centanafadine in Schedule III, interim final rule, Federal Register volume 91, page 68470, October 30, 2026, Docket No. DEA-1743: the rule is effective October 30, 2026, and comments are due November 30, 2026. DEA interim final rule in the Federal Register.

Please read this part

This article is educational and is not medical advice. It does not create a treatment relationship. The trials it describes ran for six weeks, used a placebo comparison, and enrolled defined age groups, so their averages cannot predict your response. Do not start, stop, or change a medicine, and do not drop therapy or a working routine, because of anything written here. Raise the question in care, where it can be weighed properly.

If you are having thoughts of harming yourself, help is available now: call or text 988, text HOME to 741741 for Crisis Text Line, or call the NAMI Helpline at 1-800-950-6264. This practice is not an emergency service. If someone is in immediate danger, call 911. The crisis page lists more options.